Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.84 |
| ▸ | HTT | P42858 | 2/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.84 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.84 |
| ▸ | TUBB | P07437 | 2/20 | 0.84 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.84 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.84 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.84 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.84 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.84 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.84 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.84 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.84 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.84 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.84 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nocodazole SCHEMBL9477 | 1.00 | ABL1 (0.84) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL8009081 | 1.00 | ABL1 (0.84) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL7615542 | 0.99 | ABL1 (0.82) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL8198291 | 0.96 | ABL1 (0.77) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL8195415 | 0.96 | ABL1 (0.77) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL22418403 | 0.95 | ABL1 (0.76) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL29573963 | 0.91 | ABL1 (1.00) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL2324427 | 0.91 | ABL1 (1.00) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| Nocodazole SCHEMBL8186933 | 0.90 | ABL1 (0.68) | ABL1ALDH1A1LMNACYP1A2CYP2C9 | |
| SCHEMBL4204424 | 0.87 | NPC1 (0.64) | ABL1ALDH1A1LMNACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 497 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| EP-3612231-B1 | DRUG DELIVERY SYSTEM | LIPOGEMS INT S P A (IT) | 2025-06-25 | — | — | EP | claimed |
| EP-4086250-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-12-11 | — | — | EP | claimed |
| EP-4011887-B1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | CALITHERA BIOSCIENCES INC (US) | 2024-07-31 | — | — | EP | claimed |
| EP-3888658-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | claimed |
| US-20230405156-A1 | METHODS OF DIAGNOSING AND PROGNOSING CANCERS OF THE HEAD AND NECK | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-12-21 | — | — | US | claimed |
| EP-3313443-B9 | COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER | IMMUNOMEDICS INC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-3313443-B1 | COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER | IMMUNOMEDICS INC (US) | 2023-06-07 | — | — | EP | claimed |
| EP-3021832-B9 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-03-15 | — | — | EP | claimed |
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| EP-3166976-B1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-02-23 | — | — | EP | claimed |
| EP-3693375-B1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | CALITHERA BIOSCIENCES INC (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3704090-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748838-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637510-B2 | Oncolytic virus compositions and methods for the treatment of cancer | CITY OF HOPE (US) | 2026-05-26 | — | — | US | disclosed |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022023772-A1 | ANTAGONIST COMPOUNDS | AdoRx Therapeutics Limited (GB) | 2022-02-03 | — | — | WO | disclosed |
| US-20220023307-A1 | METHOD OF TREATING METASTATIC CANCER IN A SUBJECT WITH A PROTEIN INHIBITOR | CITY UNIVERSITY OF HONG KONG (HK) | 2022-01-27 | — | — | US | disclosed |
| EP-3941905-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637510-B2 | Oncolytic virus compositions and methods for the treatment of cancer | CD47, IGLV6-57, STING1 | ABL1 1509/4885ALDH1A1 4561/4885LMNA 3051/4885 |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | YTHDF3, YTHDF1, YTHDF2 | ABL1 162/4885ALDH1A1 4643/4885LMNA 3347/4885 |
| US-20220023307-A1 | METHOD OF TREATING METASTATIC CANCER IN A SUBJECT WITH A PROTEIN INHIBITOR | NCBP1, NCBP2, CAPN9 | ABL1 3258/4885ALDH1A1 4456/4885LMNA 2853/4885 |
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | SI, PIM1, PIM3 | ABL1 3019/4885ALDH1A1 3167/4885LMNA 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.